• Shigella Vaccines Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Shigella Vaccines Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
The new research trial drives the Shigella vaccines market:
The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47
Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop
vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of
diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have
developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully.
Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1
clinical trials.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1110
Top Key Players:
The key players present in the global shigella vaccines market include MSD Wellcome Trust
Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and
GlaxoSmithKline plc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.